April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Fundus Autofluorescence Findings In Patients Diagnosed With Macular Telangiectasia Type 2
Author Affiliations & Notes
  • Irene A. Barbazetto
    Vitreous-Retina-Macula-Consultants of New York, New York, New York
  • K. Bailey Freund
    Vitreous-Retina-Macula-Consultants of New York, New York, New York
  • James Klancnik
    Vitreous-Retina-Macula-Consultants of New York, New York, New York
  • Michael Cooney
    Vitreous-Retina-Macula-Consultants of New York, New York, New York
  • Lawrence Yannuzzi
    Vitreous-Retina-Macula-Consultants of New York, New York, New York
  • Footnotes
    Commercial Relationships  Irene A. Barbazetto, None; K. Bailey Freund, Genentech (F), Genentech, Allergan, Alimera (C); James Klancnik, None; Michael Cooney, None; Lawrence Yannuzzi, None
  • Footnotes
    Support  Macula Foundation
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4520. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Irene A. Barbazetto, K. Bailey Freund, James Klancnik, Michael Cooney, Lawrence Yannuzzi; Fundus Autofluorescence Findings In Patients Diagnosed With Macular Telangiectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4520.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate fundus autofluorescence findings at different stages of macular telangiectasia type 2 (MacTel 2) and to document their change over time.

 
Methods:
 

Retrospective analysis of patients diagnosed with MacTel 2 who underwent fundus autofluorescence (FAF) imaging as part of their clinical work-up. FAF imaging was performed using the Heidelberg Retina angiograph II, Spectralis HRA+OCT (Heidelberg Engineering Inc., Heidelberg, Germany) or a Topcon fundus camera (Topcon Optical, Tokyo, Japan) fitted with filters according to Spaide’s specifications (excitation at 580nm, barrier filters at 695nm). Clinical information including age, sex and best-corrected visual acuity, fluorescein angiographic findings, and optical coherence tomography (OCT) observations were recorded. Prior treatments including intravitreal anti-VEGF therapy were reviewed.

 
Results:
 

Fifty-two eyes of 26 patients [8 male; 18 female; mean age: 62.7 years (39 - 82 years)] were included in the study. Thirteen patients had additional FAF examinations with a mean follow-up of 25.4 months. Nine patients had treatment with intravitreal anti-VEGF therapy. Two patients had prior intravitreal steroid injections. At baseline, 16 eyes were classified as stage 1, 12 eyes as stage 2, 12 eyes as stage 3 and 10 as stage 4 (Yannuzzi classification). Two eyes did not show any angiographic evidence of telangiectasia. Either increased areas of hyper- or iso-FAF were seen in stages 1 and 2 eyes. Eyes with more advanced stages showed heterogenous findings including hypofluorescence related to pigment and hyper-FAF related to subretinal neovascularization. Changes in FAF patterns over time were seen in all but 1 patient with stages 3-4 and in 3 eyes with stages 1 and 2.

 
Conclusions:
 

Changes in FAF correlate with disease severity in eyes with MacTel 2. Advanced stages show more extensive FAF alterations, which seem more likely to progress over time. Larger prospective studies, such as the MacTel study, are needed to verify these observations and to determine if FAF changes are solely related to advanced disease or possibly accelerated by intravitreal anti-VEGF therapy.

 
Keywords: retina • imaging/image analysis: clinical • macular pigment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×